A new analysis from the Rush Memory and Aging Project finds people who report less frequent participation in social activities have a more rapid rate of motor decline in old age.
Medscape Medical News
Music, particularly pieces that contain crescendos or gradual increases in volume, elicits synchronized cardiovascular and respiratory responses in young people, a new study finds.
Medscape Medical News
A 10th patient taking Biogen Idec Inc's multiple sclerosis drug Tysabri has developed progressive multifocal leukoencephalopathy (PML) since it was reintroduced to the market in July 2006.
Reuters Health Information
Pharmacists are integral to the development of proactive methods to help prevent health-care-associated infections.
American Journal of Health-System Pharmacy
White-coat hypertension and masked hypertension should not be regarded as benign, say the authors of a new 10-year study. The risk of developing sustained hypertension is higher in people with the above two conditions than in those who have normal blood pressure, they found.
Heartwire
Study participants will be randomized to one of four groups: daily vitamin D (2000 IU) and fish oil (1 g); daily vitamin D and fish-oil placebo; daily vitamin-D placebo and fish oil; or daily vitamin-D placebo and fish-oil placebo and followed for five years.
Heartwire
Two editorials present opposing views on the merits and safety risks of making stimulants, particularly methylphenidate, freely available for enhancing cognitive performance in healthy adults.
Medscape Medical News
How do extra hours on the clock impact brain function?
American Journal of Epidemiology
A 40-year-old man with relapsing-remitting multiple sclerosis (MS) developed primary central nervous system lymphoma (PCNSL) after having received 21 doses of natalizumab monotherapy. PCNSL is a disease of the elderly, with the majority of patients being diagnosed in the 7th to 8th decade of life. Immunodeficiency, iatrogenic immunosuppression, and some autoimmune diseases are known as predisposing conditions, and in these patients PCNSL peaks in the 4th decade. Because there is no increased prevalence of PCNSL in MS, and the patient was otherwise not immunocompromised, an association between natalizumab therapy and PCNSL cannot be ruled out. Ann Neurol 2009;66:403-406